THERAPY DOSSIER · th-b10cfd5c85c8

Allogeneic mouse myeloid progenitor cells (mMPC)

Biologic · Cell therapy (allogeneic mouse myeloid progenitor cells); mouse reagent, preclinical

Evidence & regulatory context

Mechanism: Cell therapy (allogeneic mouse myeloid progenitor cells); mouse reagent, preclinical
Target: Not recorded
Injury models: Radiation
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 22559205 ↗2012Reported benefit

Myeloid progenitors: a radiation countermeasure that is effective when initiated days after irradiation.

MouseRadiationRecipients Balb/c and CD2F1; donor cells pooled from AKR, C57Bl/6 and FVB miceMaleIntravenous transfusionVarious cell doses, including 5 million cells (dose-reducti…From 24 h up to 7 days after irradiation

Model: Lethal total body irradiation with 60Co gamma rays (9.2 Gy and up to 15 Gy, CD2F1) or X-rays (9 Gy, Balb/c)

Cryopreserved allogeneic myeloid progenitor cells significantly improved 30-day survival in both strains after lethal irradiation. The benefit was cell-dose dependent and remained significant when administration was delayed up to 7 days, and up to 5 days at doses as high as 14 Gy.

Extraction: extract · Supplied extraction confidence: 0.75. Machine-extracted fields require source verification.

Loading the evidence…